GSC
EGRX

Ground Swell Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ground Swell Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-400
Closed -$6K – 2833
2014
Q2 		$6K Buy
+400
New +$4.56K 0.01% 1011

Other funds holding EGRX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Ground Swell Capital's EGRX Position: Q3 2014 in Review

Ground Swell Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2014, closing a stake of 400 shares — an estimated $6K sold.

Ground Swell Capital first reported a position in EGRX in Q2 2014 and held it in 1 quarter. The position peaked at $6K in Q2 2014. 27 funds tracked by Wall St. Rank hold EGRX as of Q3 2014.

  • Ground Swell Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 400 Eagle Pharmaceuticals, Inc. shares in Q3 2014, an estimated $6K.
  • Ground Swell Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's Eagle Pharmaceuticals, Inc. position peaked at $6K in Q2 2014.
  • 27 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.